Business Insight & People News
Pharmaceutical Preparations
Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.
Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.
| Insider | Reported role | Shares | Value | Last action |
|---|---|---|---|---|
| Officers 4 | ||||
| Kenneth Patrick Lorton | COO | 89,241 | $1.79M | S Open-market sale Mar 5, 2026 position reported |
| Robert Lorne Abel | Executive | 55,897 | $1.12M | S Open-market sale Mar 4, 2026 position reported |
| Yvonne Tran | General Counsel | 52,683 | $1.06M | S Open-market sale Mar 5, 2026 position reported |
| Rachit Jain | CFO | 52,596 | $1.06M | S Open-market sale Jul 16, 2026 position reported |
| Officers who also sit on the board 2 | ||||
| Ramy Farid | CEO | 330,824 | $6.65M | M Option exercise or conversion Apr 17, 2026 position reported |
| Karen Akinsanya | Executive | 69,956 | $1.41M | S Open-market sale Mar 5, 2026 position reported |
| Directors 6 | ||||
| Richard Friesner | Board Member | 1,405,477 | $28.24M | G Bona fide gift Jun 26, 2026 position reported |
| Arun Oberoi | Board Member | 17,247 | $346.5K | A Grant or award Jun 22, 2026 position reported |
| Gary L. Ginsberg | Board Member | 17,247 | $346.5K | A Grant or award Jun 22, 2026 position reported |
| Michael Lynton | Board Member | 17,247 | $346.5K | A Grant or award Jun 22, 2026 position reported |
| Nancy Thornberry | Board Member | 17,247 | $346.5K | A Grant or award Jun 22, 2026 position reported |
| Bridget A van Kralingen | Board Member | 11,499 | $231.0K | A Grant or award Jun 22, 2026 position reported |
The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.
A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 16, 2026 | Rachit Jain | S Open-market sale | 875 | $15.60 | $13.7K | SEC filing ↗ |
| Jun 26, 2026 | Richard Friesner | G Bona fide gift | 679,373 | $0.00 | $0 | SEC filing ↗ |
| Jun 26, 2026 | Richard Friesner | G Bona fide gift | 679,373 | $0.00 | $0 | SEC filing ↗ |
| Jun 22, 2026 | Richard Friesner | A Grant or award | 8,141 | $0.00 | $0 | SEC filing ↗ |
| Jun 22, 2026 | Nancy Thornberry | A Grant or award | 8,141 | $0.00 | $0 | SEC filing ↗ |
| Jun 22, 2026 | Michael Lynton | A Grant or award | 8,141 | $0.00 | $0 | SEC filing ↗ |
| Jun 22, 2026 | Bridget A van Kralingen | A Grant or award | 8,141 | $0.00 | $0 | SEC filing ↗ |
| Jun 22, 2026 | Arun Oberoi | A Grant or award | 8,141 | $0.00 | $0 | SEC filing ↗ |
| Jun 22, 2026 | Gary L. Ginsberg | A Grant or award | 8,141 | $0.00 | $0 | SEC filing ↗ |
| Apr 17, 2026 | Ramy Farid | M Option exercise or conversion | 74,527 | $3.07 | $228.8K | SEC filing ↗ |
| Apr 17, 2026 | Ramy Farid | S Open-market sale | 43,000 | $12.21 | $525.0K | SEC filing ↗ |
| Apr 17, 2026 | Ramy Farid | M Option exercise or conversion | 43,000 | $3.07 | $132.0K | SEC filing ↗ |
| Apr 16, 2026 | Rachit Jain | S Open-market sale | 844 | $12.75 | $10.8K | SEC filing ↗ |
| Apr 16, 2026 | Ramy Farid | S Open-market sale | 43,000 | $12.33 | $530.2K | SEC filing ↗ |
| Apr 16, 2026 | Ramy Farid | M Option exercise or conversion | 43,000 | $3.07 | $132.0K | SEC filing ↗ |
| Mar 5, 2026 | Rachit Jain | S Open-market sale | 1,631 | $12.90 | $21.0K | SEC filing ↗ |
| Mar 5, 2026 | Yvonne Tran | S Open-market sale | 1,094 | $12.90 | $14.1K | SEC filing ↗ |
| Mar 5, 2026 | Kenneth Patrick Lorton | S Open-market sale | 1,222 | $12.90 | $15.8K | SEC filing ↗ |
| Mar 5, 2026 | Karen Akinsanya | S Open-market sale | 1,366 | $12.90 | $17.6K | SEC filing ↗ |
| Mar 5, 2026 | Ramy Farid | S Open-market sale | 3,661 | $12.91 | $47.3K | SEC filing ↗ |
| Mar 4, 2026 | Robert Lorne Abel | S Open-market sale | 1,300 | $12.81 | $16.7K | SEC filing ↗ |
| Mar 2, 2026 | Rachit Jain | A Grant or award | 17,130 | $0.00 | $0 | SEC filing ↗ |
| Mar 2, 2026 | Robert Lorne Abel | A Grant or award | 20,682 | $0.00 | $0 | SEC filing ↗ |
| Mar 2, 2026 | Robert Lorne Abel | A Grant or award | 17,130 | $0.00 | $0 | SEC filing ↗ |
| Mar 2, 2026 | Yvonne Tran | A Grant or award | 13,788 | $0.00 | $0 | SEC filing ↗ |
From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.
The report an officer, director or large shareholder must file after trading their own company’s stock.
7 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.
This is not the full list. SEC rules only require a company to name its significant subsidiaries.
Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.
| Subsidiary | Organised in |
|---|---|
| Reo Discovery Limited | Ireland |
| Schrödinger GmbH | Germany |
| Schrödinger India Private Limited | India |
| Schrodinger Korea LLC | South Korea |
| Schrödinger Technologies Ltd | United Kingdom |
| Schrödinger, KK | Japan |
| Schrödinger, LLC | Delaware |
A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.
Think a number here is wrong? Open the linked filing and compare — how to report it.
Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.
Share count: weighted average over the reporting period (us-gaap:WeightedAverageNumberOfSharesOutstandingBasic), taken from
Schrodinger, Inc.’s own filings and multiplied by our closing price.
≈ Not a single-day figure — treat this
market cap and its rank as approximate.
Full method.
this company did not tag a cover-page share count we could read, so the figure is the average number of shares outstanding across the whole reporting period rather than a count on any single day. If the company issued or bought back stock during the period, the true count today is higher or lower than this.
We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Schrodinger, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.